Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX ®
Condition: Prostate Cancer Interventions: Drug: LY01005; Drug: ZOLADEX® 3.6 mg Sponsor: Luye Pharma Group Ltd. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials